Cargando...

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases

Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Therap Adv Gastroenterol
Autores principales: Sieczkowska, Joanna, Jarzębicka, Dorota, Meglicka, Monika, Oracz, Grzegorz, Kierkus, Jaroslaw
Formato: Artigo
Lenguaje:Inglês
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4984328/
https://ncbi.nlm.nih.gov/pubmed/27582886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16650155
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!